Do analysts recommend MOR or RLMD?

Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 89.57%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media prefer MOR or RLMD?

In the previous week, Relmada Therapeutics had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for MorphoSys. Relmada Therapeutics' average media sentiment score of 0.85 beat MorphoSys' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MorphoSys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, GPCR or RLMD?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is GPCR or RLMD more profitable?

Structure Therapeutics' return on equity of -24.91% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Relmada Therapeutics N/A -71.22% -64.46%

Is RLMD or RLAY more profitable?

Relay Therapeutics' return on equity of -43.94% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Relay Therapeutics N/A -43.94% -40.11%

Does the media refer more to RLMD or RLAY?

In the previous week, Relay Therapeutics had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 6 mentions for Relay Therapeutics and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.85 beat Relay Therapeutics' score of 0.50 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RLMD or ARQT?

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 3 mentions for Relmada Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Relmada Therapeutics' score of 0.85 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, IRON or RLMD?

Disc Medicine is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is IRON or RLMD more profitable?

Disc Medicine's return on equity of -36.94% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Relmada Therapeutics N/A -71.22% -64.46%

Does the media refer more to IRON or RLMD?

In the previous week, Disc Medicine had 6 more articles in the media than Relmada Therapeutics. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.85 beat Disc Medicine's score of 0.44 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relmada Therapeutics (RLMD) Competitors

$6.33 -0.09 (-1.40%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$6.32 0.00 (-0.08%)

As of 06/3/2026 07:03 PM Eastern

Compare

RLMD vs. MOR, GPCR, RLAY, ARQT, and IRON

Should you buy Relmada Therapeutics stock or one of its competitors? MarketBeat compares Relmada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relmada Therapeutics include MorphoSys (MOR), Structure Therapeutics (GPCR), Relay Therapeutics (RLAY), Arcutis Biotherapeutics (ARQT), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.

How does Relmada Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Relmada Therapeutics has lower revenue, but higher earnings than MorphoSys. Relmada Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 89.57%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Relmada Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Relmada Therapeutics' return on equity of -71.22% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Relmada Therapeutics	N/A	-71.22%	-64.46%

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for MorphoSys. Relmada Therapeutics' average media sentiment score of 0.85 beat MorphoSys' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MorphoSys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats MorphoSys on 12 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Structure Therapeutics' return on equity of -24.91% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Relmada Therapeutics	N/A	-71.22%	-64.46%

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Relmada Therapeutics' score of 0.85 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Structure Therapeutics	Very Positive
Relmada Therapeutics	Positive

Structure Therapeutics presently has a consensus price target of $109.25, indicating a potential upside of 190.95%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 89.57%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Structure Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Structure Therapeutics beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Relay Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Relmada Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Relay Therapeutics	$15.35M	190.97	-$276.48M	-$1.57	N/A

Relay Therapeutics' return on equity of -43.94% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Relay Therapeutics	N/A	-43.94%	-40.11%

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 89.57%. Relay Therapeutics has a consensus price target of $23.30, suggesting a potential upside of 52.29%. Given Relmada Therapeutics' higher probable upside, research analysts clearly believe Relmada Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Relmada Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

In the previous week, Relay Therapeutics had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 6 mentions for Relay Therapeutics and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.85 beat Relay Therapeutics' score of 0.50 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relay Therapeutics beats Relmada Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to Arcutis Biotherapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Relmada Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Arcutis Biotherapeutics has higher revenue and earnings than Relmada Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Arcutis Biotherapeutics	$376.07M	7.10	-$16.14M	-$0.03	N/A

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 89.57%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 59.25%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 3 mentions for Relmada Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Relmada Therapeutics' score of 0.85 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Relmada Therapeutics (NASDAQ:RLMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Disc Medicine had 6 more articles in the media than Relmada Therapeutics. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.85 beat Disc Medicine's score of 0.44 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine currently has a consensus target price of $105.30, suggesting a potential upside of 49.68%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 89.57%. Given Relmada Therapeutics' higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Disc Medicine is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Disc Medicine has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Disc Medicine's return on equity of -36.94% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Disc Medicine and Relmada Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$673.40M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-5.81	17.69	22.17	24.18
Price / Sales	N/A	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	5.36	3.85	9.84	6.72
Net Income	-$57.38M	$75.85M	$3.57B	$337.19M
7 Day Performance	-12.69%	-3.99%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	757.84%	19.65%	26.49%	33.10%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.0983 of 5 stars	$6.33 -1.4%	$12.00 +89.6%	+807.8%	$673.40M	N/A	N/A	10
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
GPCR Structure Therapeutics	3.2627 of 5 stars	$37.50 -4.7%	$109.25 +191.3%	+70.9%	$2.80B	N/A	N/A	136	Positive News
RLAY Relay Therapeutics	2.505 of 5 stars	$16.42 +16.9%	$23.30 +41.9%	+365.0%	$2.69B	$10.68M	N/A	330	Options Volume
ARQT Arcutis Biotherapeutics	3.3506 of 5 stars	$20.67 -3.7%	$34.00 +64.5%	+60.9%	$2.69B	$415.62M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. MOR, GPCR, RLAY, ARQT, and IRON

How does Relmada Therapeutics compare to MorphoSys?

Summary

How does Relmada Therapeutics compare to Structure Therapeutics?

Summary

How does Relmada Therapeutics compare to Relay Therapeutics?

Summary

How does Relmada Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Relmada Therapeutics compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. MOR, GPCR, RLAY, ARQT, and IRON

How does Relmada Therapeutics compare to MorphoSys?

Do institutionals and insiders hold more shares of MOR or RLMD?

Which has preferable valuation & earnings, MOR or RLMD?

Do analysts recommend MOR or RLMD?

Is MOR or RLMD more profitable?

Which has more volatility and risk, MOR or RLMD?

Does the media prefer MOR or RLMD?

Summary

How does Relmada Therapeutics compare to Structure Therapeutics?

Is GPCR or RLMD more profitable?

Do insiders & institutionals believe in GPCR or RLMD?

Which has higher valuation & earnings, GPCR or RLMD?

Which has more risk and volatility, GPCR or RLMD?

Does the media favor GPCR or RLMD?

Do analysts recommend GPCR or RLMD?

Summary

How does Relmada Therapeutics compare to Relay Therapeutics?

Which has stronger earnings & valuation, RLMD or RLAY?

Is RLMD or RLAY more profitable?

Do institutionals & insiders hold more shares of RLMD or RLAY?

Do analysts rate RLMD or RLAY?

Which has more risk and volatility, RLMD or RLAY?

Does the media refer more to RLMD or RLAY?

Summary

How does Relmada Therapeutics compare to Arcutis Biotherapeutics?

Do institutionals and insiders have more ownership in RLMD or ARQT?

Which has more risk & volatility, RLMD or ARQT?

Is RLMD or ARQT more profitable?

Which has higher valuation and earnings, RLMD or ARQT?

Do analysts rate RLMD or ARQT?

Does the media refer more to RLMD or ARQT?

Summary

How does Relmada Therapeutics compare to Disc Medicine?

Do institutionals & insiders hold more shares of IRON or RLMD?

Does the media refer more to IRON or RLMD?

Do analysts recommend IRON or RLMD?

Which has stronger valuation and earnings, IRON or RLMD?

Which has more risk and volatility, IRON or RLMD?

Is IRON or RLMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools